Business

An update on Biocon and biosimilars

Last Tuesday, we wrote on Kiran Mazumdar Shaw and her company, the Bengaluru-based biopharmaceutical company Biocon. If you haven’t read that piece, we’d recommend you do.

Biocon, alongwith its partner US-based generic company Mylan, launched their breast cancer drug in Australia and the US Food and Drug Administration (FDA) cleared a key manufacturing unit in Malaysia to make biological products.

To access this post, you must purchase Subscription, Regular, Regular – Annual, Regular – Monthly or Student.

START YOUR DAY WITH THE MORNING CONTEXT

Subscribe to read this story and more
100+ new, deeply reported stories and 50+ shorts a year
Things Change, TMC’s weekly newsletter
Full access to the archives

By clicking on sign up, you agree to Slowform Pte Ltd’s Terms & Conditions and Privacy Policy

Already have an account? Login here or Take me to some free reads